Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Dara Khosrowshahi steps down from Grab Holdings board
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- Lockheed Martin to acquire Ultra Maritime for $3.45 billion
Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 16c
November 7, 2018 4:52 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.13, $0.16 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $49.14 million versus the consensus estimate of $49.44 million.
GUIDANCE:
Vanda reiterates 2018 net product sales guidance of $180 million to $200 million.
For... More
